-
41
-
42
One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic
Published 2024-12-01“…Materials and Methods We have vaccinated 292 patients with all hematological malignancies with a third dose of mRNA COMIRNATY vaccine with a 12‐month follow‐up period in our center in Ostrava, Czech Republic. …”
Get full text
Article -
43
Synthesis and Anti-Cancer Activity In Vitro of Synephrine Derivatives
Published 2024-12-01Subjects: Get full text
Article -
44
Editorial: Two decades of targeted therapies in hematology: new targets and novel combinations
Published 2025-01-01Subjects: Get full text
Article -
45
CRISPR-Cas9 in basic and translational aspects of cancer therapy
Published 2024-11-01Subjects: Get full text
Article -
46
Critically ill adult patients with acute leukemia: a systematic review and meta-analysis
Published 2025-01-01Subjects: Get full text
Article -
47
Pharmacological activity of OST-01, a natural product from baccharis coridifolia, on breast cancer cells
Published 2025-02-01Get full text
Article -
48
A Rare Case of Immunotactoid Glomerulopathy Associated with Hodgkin Lymphoma
Published 2021-01-01“…In hematologic malignancies, multiple myeloma and other mature B-cell malignancies are the most common hematologic malignancies, and Hodgkin lymphoma (HL) is extremely rare. …”
Get full text
Article -
49
-
50
Bacteremia due to Leuconostoc pseudomesenteroides in a Patient with Acute Lymphoblastic Leukemia: Case Report and Review of the Literature
Published 2016-01-01“…Infections due to Leuconostoc species have been reported in various immunocompromised patients, but little is known about such infection in patients with hematologic malignancies. We report a case of Leuconostoc infection in a 44-year-old woman with acute lymphoblastic leukemia. …”
Get full text
Article -
51
The AST/ALT (De Ritis) ratio as a significant prognostic factor in myelodysplastic syndrome
Published 2024-12-01Get full text
Article -
52
Malignant Lymphoma Presenting as Fulminant Hepatic Failure
Published 1989-01-01“…A review of the literature yields 11 other cases with hematologic malignancies with similar presentation. To the authors’ knowledge this is the first case in which cell marker analysis was performed. …”
Get full text
Article -
53
Lenalidomide-Associated ITP
Published 2011-01-01“…Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia. …”
Get full text
Article -
54
T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications
Published 2011-01-01“…In hematologic malignancies, the microenvironment is often characterized by nonneoplastic cells with peculiar phenotypic and functional features. …”
Get full text
Article -
55
Spontaneous Tumor Lysis Syndrome due to Uterine Leiomyosarcoma with Lung Metastases
Published 2017-01-01“…TLS is usually seen after the initiation of chemotherapy for hematologic malignancies. TLS occurring spontaneously, without initiation of chemotherapy, is rare and its occurrence in solid tumors is rarer still. …”
Get full text
Article -
56
Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy
Published 2023-10-01“…The overexpression of myeloid cell leukemia-1 (MCL-1) has been identified in numerous hematologic malignancies and solid tumors. Currently, there are no selective MCL-1 inhibitors. …”
Get full text
Article -
57
Sarcoidosis and Its Splenic Wonder: A Rare Case of Isolated Splenic Sarcoidosis
Published 2018-01-01“…Among the many considerations are hematologic malignancies, primary splenic or metastatic tumors, infiltrative disorders, inflammatory disorders, and infections. …”
Get full text
Article -
58
CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity
Published 2025-01-01“…Chimeric Antigen Receptor (CAR)-T cell therapy has rapidly emerged as a groundbreaking approach in cancer treatment, particularly for hematologic malignancies. However, the application of CAR-T cell therapy in solid tumors remains challenging. …”
Get full text
Article -
59
-
60